Compare ELTX & FEIM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ELTX | FEIM |
|---|---|---|
| Founded | 2011 | 1961 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Electrical Products |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 63.3M | 722.9M |
| IPO Year | 2014 | 1994 |
| Metric | ELTX | FEIM |
|---|---|---|
| Price | $1.92 | $85.97 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 2 |
| Target Price | $13.67 | ★ $95.50 |
| AVG Volume (30 Days) | ★ 324.7K | 309.7K |
| Earning Date | 11-12-2026 | 09-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 39.29 | N/A |
| EPS | N/A | ★ 0.41 |
| Revenue | $2,301,000.00 | ★ $63,227,000.00 |
| Revenue This Year | N/A | $30.80 |
| Revenue Next Year | N/A | $26.18 |
| P/E Ratio | ★ N/A | $205.98 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.71 | $26.05 |
| 52 Week High | $16.00 | $89.76 |
| Indicator | ELTX | FEIM |
|---|---|---|
| Relative Strength Index (RSI) | 23.58 | 60.34 |
| Support Level | $1.71 | $48.49 |
| Resistance Level | $3.32 | $89.68 |
| Average True Range (ATR) | 0.11 | 4.14 |
| MACD | 0.04 | -0.04 |
| Stochastic Oscillator | 29.88 | 52.36 |
Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.
Frequency Electronics Inc is a world leader in precision time and frequency generation technology, which is incorporated into commercial and U.S. Government satellites, Command, Control, Communication, Computer, Intelligence, Surveillance and Reconnaissance, and Electronic Warfare systems. Its technology is used for a wide range of space and non-space applications. The company has two segments FEI-NY, and FEI-Zyfer. Majority of revenue come from FEI-NY which provides precision time, frequency generation and synchronization products and subsystems that are found on-board satellites, in ground-based communication systems and imbedded in mobile platforms operated by the U.S. military.